When Ultra-Sensitive Testing Becomes a Double-Edged Sword
Nitrosamine impurity testing has become one of the most critical analytical requirements in pharmaceutical development. Since regulators including the FDA, EMA, and ICH introduced increasingly stringent expectations for mutagenic impurities, pharmaceutical companies have been required to demonstrate that nitrosamines are either absent or controlled to extremely low parts-per-billion (ppb) levels.
While this heightened sensitivity improves patient safety, it also introduces a lesser-known analytical challenge. At ultra-trace concentrations, the sample preparation process itself can alter the chemistry of a drug substance, generating impurities that were never present in the manufactured API. These analytical artifacts can produce false-positive results, trigger unnecessary investigations, delay regulatory submissions, and increase development costs.
One recent project at PI Health Sciences demonstrated exactly how this challenge can arise—and how a science-driven analytical strategy prevented a false-positive Nitrosamine Drug Substance-Related Impurity (NDSRI) from becoming a regulatory concern.
Why NDMA Testing Methods Don’t Always Transfer to NDSRI Programs
Most nitrosamine testing services built their core methods around the “classic” nitrosamines — NDMA, NDEA, NMBA, NDIPA — small, well-characterized molecules with established LC-MS/MS and GC-MS protocols and years of interlaboratory data behind them. NDSRIs are a different animal. Because an NDSRI is structurally derived from the API itself, every method has to be built around that specific molecule’s chemistry, its amine functionality, and the exact matrix it sits in. A generic nitrosamine panel validated for NDMA and NDEA won’t necessarily catch — or accurately quantify — an NDSRI unique to a given drug substance.
This case study is a clear illustration of why that distinction matters.
When the Test Becomes the Problem
While developing a high-sensitivity LC-MS/MS method to quantify NDSRIs in a structurally complex small-molecule API, the PI Health Sciences analytical team observed something that didn’t add up: NDSRI quantification that wasn’t reproducible from run to run. Values drifted. Peaks that shouldn’t have been there occasionally showed up. On paper, it looked like the API itself had a nitrosamine problem.
Root-cause investigation told a different story. Nitric acid, used earlier in the synthetic route as a process reagent, was carrying forward in trace residual form into the final API isolation step. Once in the aqueous sample preparation matrix, residual nitrate and nitrite ions were reacting in situ with secondary and tertiary amine groups in the molecule — generating NDSRIs that had never existed in the bulk drug substance. They were artifacts of the analysis itself, not the manufacturing process.
That distinction matters enormously for any nitrosamine impurity testing program. An artifact NDSRI can trigger the exact same regulatory red flags as a genuine impurity, threatening to stall a filing over a problem that doesn’t actually exist in the drug product.
Engineering the Reaction Out of the Method
Rather than accept the false-positive risk or attempt a costly process change, the team built a dual-action sample matrix modification to suppress the in situ nitrosation reaction without disturbing the API itself:
Selective nitrite scavenging. After screening several candidate scavengers, the team identified ascorbic acid as the most effective option. Added directly into the sample preparation matrix, it rapidly neutralized residual nitrite before it had a chance to react with the API’s secondary amine groups — bringing method repeatability and accuracy back within acceptable limits.
Reactive inhibition via diluent chemistry. Ammonium bicarbonate was introduced as a diluent additive, further suppressing the reactivity of any remaining trace nitrite throughout preparation and the full quantification cycle.
Orthogonal confirmation by ion chromatography. To prove — not just assume — that residual nitrite/nitrate carryover was the true root cause, the team developed and validated a standalone ion chromatography (IC) method to independently quantify these inorganic ions within the compound matrix. The IC data confirmed the LC-MS/MS findings and gave the client an evidence-backed root-cause narrative for their regulatory submission.
The Outcome
With the nitrosation pathway chemically shut down before injection, the optimized LC-MS/MS method delivered strong repeatability, recovery, and accuracy across all targeted ppb levels. The client avoided a false-positive regulatory rejection and secured a defensible CMC data package for their global filing — without reformulating the API or reworking the synthetic route.
What This Means for Your Nitrosamine Testing Program
Artifact NDSRI formation is easy to miss and expensive to misdiagnose, and it’s a risk that generic NDMA testing panels aren’t built to catch. If your team is seeing inconsistent nitrosamine quantification, non-reproducible peaks, or unexplained NDSRI signals in a complex API matrix, the cause may not be your drug substance — it may be your sample preparation chemistry.
With FDA confirmatory testing expectations already in effect and ongoing lifecycle monitoring now a standing requirement, choosing the right nitrosamine testing services partner matters as much as the method itself. When evaluating a lab for nitrosamine impurity testing or NDSRI-specific work, look for:
- Product-specific method development, not a one-size-fits-all NDMA/NDEA panel adapted after the fact
- Documented root-cause investigation capability — the ability to distinguish a genuine impurity from an analytical artifact, with orthogonal data (like ion chromatography) to back it up
- Experience with matrix effects in complex, high-concentration API and excipient backgrounds
- A track record of submission-ready documentation that holds up under FDA, EMA, and ICH M7 scrutiny
Need to de-risk your mutagenic impurity profile? Contact our analytical team to schedule an in silico risk evaluation or discuss custom LC-MS/MS method development for your NDMA, NDEA, or NDSRI testing program.
Explore our Analytical Services